AAPG
HealthcareAscentage Pharma Group International · Biotechnology · $2B
What is Ascentage Pharma Group International?
Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing targeted therapies for cancers, chronic hepatitis B, and age-related diseases, with operations centered in Mainland China.
Ascentage Pharma advances a pipeline of small-molecule drug candidates designed to restore or trigger programmed cell death in cancer cells. Its lead programs target specific protein interactions involved in tumor survival and resistance. The company also engages in clinical trial operations, medical research services, and maintains collaboration relationships with other biotechnology and pharmaceutical companies to advance its candidates.
The company is headquartered in Suzhou, China.
- HQP1351 — a BCR-ABL inhibitor targeting resistant leukemia mutations including T315I
- APG-2575 — an oral Bcl-2 selective inhibitor for blood cancers and solid tumors
- APG-115 — an oral MDM2-p53 inhibitor for solid tumors and hematological malignancies
- APG-1252 — a dual Bcl-2/Bcl-xL inhibitor targeting lung cancers and lymphoma
Is AAPG a Good Stock to Buy?
UQS Score rates AAPG as Poor overall, reflecting significant challenges across multiple evaluation pillars.
The Growth and Risk pillars both land at Neutral, suggesting the pipeline carries some forward potential and that near-term risk is not at the extreme end of the spectrum for a clinical-stage biotech.
Quality and Moat are both rated Weak, indicating limited financial durability and no clear competitive entrenchment at this stage. Valuation is rated Elevated, which adds further caution for prospective investors.
See the exact pillar breakdown and full financial metrics by signing up for a Pro membership at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AAPG pay dividends?
No — Ascentage Pharma Group International does not currently pay a dividend.
AAPG does not pay a dividend, which is typical for clinical-stage biotechnology companies. Capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions. Investors in this space generally look to potential long-term value creation from successful drug development rather than income.
When does AAPG report earnings?
Ascentage Pharma reports earnings on a quarterly cadence, consistent with standard practice for companies listed on major exchanges.
As a clinical-stage company, revenue generation remains limited and results are largely shaped by research spending, collaboration income, and pipeline milestones rather than commercial sales. Quarterly reports provide updates on trial progress and cash runway.
For the most recent quarter's results, visit Ascentage Pharma's investor relations page directly.
AAPG Price History
+44.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Ascentage Pharma Group International?
Based on Ascentage Pharma Group International's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
AAPG Long-term Outlook
With Growth rated Neutral, the pipeline offers some potential catalysts — particularly if lead candidates advance through clinical milestones. However, Weak Quality and Moat ratings reflect the inherent uncertainty of pre-commercial biotech. The Elevated Valuation rating suggests the market may already be pricing in optimistic outcomes, leaving limited room for error if trials face setbacks.
Growth drivers
- Clinical advancement of HQP1351 and APG-2575 toward regulatory approval in China and potentially broader markets
- Expansion of collaboration agreements with established pharmaceutical partners
- Growing unmet need in targeted oncology and chronic HBV treatment
Key risks
- Clinical trial failure or delays across multiple pipeline candidates
- Elevated valuation relative to the company's current development stage
- Ongoing cash consumption with no commercial product revenue yet established
AAPG vs Peers
Ascentage Pharma operates in a competitive clinical-stage oncology landscape alongside several peers pursuing similar targeted therapy approaches.
Definium focuses on differentiated oncology mechanisms, competing for similar investor attention in the clinical-stage biotech space.
Celldex pursues immunotherapy and antibody-based approaches to cancer, representing a different but overlapping therapeutic strategy.
Adaptive leverages immune medicine and T-cell mapping technology, offering a distinct platform-based model compared to Ascentage's small-molecule focus.
Frequently Asked Questions
What does Ascentage Pharma do?
Ascentage Pharma is a clinical-stage biotechnology company developing small-molecule therapies targeting cancer cell survival pathways, chronic hepatitis B, and age-related diseases. Its pipeline includes BCR-ABL inhibitors, Bcl-2 inhibitors, and MDM2-p53 pathway modulators, primarily advancing in Mainland China with global collaboration partnerships.
Does AAPG pay dividends?
No, AAPG does not currently pay a dividend. Clinical-stage biotechnology companies typically reinvest all available capital into research and clinical development. Investors should not expect income distributions until the company reaches commercial-stage profitability, which remains a future milestone.
When does AAPG report earnings?
Ascentage Pharma follows a quarterly earnings reporting cadence. Because our data source does not cover specific upcoming dates, check the company's official investor relations page for the most current schedule and recent financial disclosures.
Is AAPG a good stock to buy?
UQS Score rates AAPG as Poor, with Weak scores on Quality and Moat and an Elevated Valuation rating. While Growth and Risk are Neutral, the overall profile reflects the high uncertainty typical of pre-commercial biotech. The complete pillar breakdown is available to Pro members at UQS Score.
Is AAPG overvalued?
The UQS Valuation pillar for AAPG is rated Elevated, suggesting the current market price may not offer a wide margin of safety relative to the company's development stage. Clinical-stage companies often carry premium valuations based on pipeline potential, which increases downside risk if trials disappoint.
How does AAPG compare to its competitors?
Compared to peers like Celldex Therapeutics and Adaptive Biotechnologies, Ascentage Pharma is differentiated by its small-molecule apoptosis-focused pipeline and its primary operational base in China. Each company pursues distinct mechanisms, making direct comparison dependent on pipeline stage and therapeutic area overlap.
What is AAPG's market cap bracket?
AAPG is classified as a mid-cap stock. This places it in a range where the company has meaningful market recognition but has not yet achieved the scale associated with large or mega-cap biotechnology firms.
Who founded Ascentage Pharma?
Founding details for Ascentage Pharma are widely available through the company's official disclosures and public filings. The company is headquartered in Suzhou, China, and has built its pipeline through internal research and external collaborations with global pharmaceutical partners.
Is AAPG a long-term quality investment?
As a long-term quality indicator, UQS Score rates AAPG as Poor. Weak Quality and Moat pillars reflect limited financial durability and competitive entrenchment at this stage. Long-term outcomes depend heavily on clinical trial success — a factor that introduces substantial uncertainty for any multi-year investment thesis.
What is the main competitive advantage of Ascentage Pharma?
Ascentage Pharma's potential differentiation lies in its focus on apoptosis-restoring mechanisms and its pipeline breadth across multiple cancer types and HBV. However, the UQS Moat pillar is rated Weak, indicating that durable competitive advantages have not yet been firmly established at this clinical stage.
Unlock Full AAPG Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings for AAPG
- ✓Access full financial metrics and trend data
- ✓Compare AAPG side-by-side with peers on every quality dimension
- ✓See valuation context relative to sector benchmarks
- ✓Get the complete analyst-style breakdown available to Pro members
Pro Analysis
AAPG — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 26.6 | 4.6 | 31.0 | 56.3 | 43.3 | 0.0 | +1.1 |
| May 10, 2026 | 25.5 | 0.0 | 31.0 | 56.3 | 43.3 | 0.0 | -1.1 |
| May 4, 2026 | 26.6 | 4.6 | 31.0 | 56.3 | 43.3 | 0.0 | -0.9 |
| Apr 28, 2026 | 27.5 | 7.9 | 31.0 | 56.3 | 43.3 | 0.0 | +0.1 |
| Apr 25, 2026 | 27.4 | 7.8 | 31.0 | 56.3 | 43.3 | 0.0 | -0.1 |
| Apr 24, 2026 | 27.5 | 8.0 | 31.0 | 56.3 | 43.3 | 0.0 | +0.1 |
| Apr 23, 2026 | 27.4 | 7.7 | 31.0 | 56.3 | 43.3 | 0.0 | 0.0 |
| Apr 2, 2026 | 27.4 | 7.5 | 31.0 | 56.3 | 43.3 | 0.0 | — |
AAPG — Pillar Breakdown
Quality
— 4.6/100 (25%)Ascentage Pharma Group International currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 56.3/100 (20%)Ascentage Pharma Group International demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 43.3/100 (15%)Ascentage Pharma Group International has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Ascentage Pharma Group International appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 31/100 (25%)Ascentage Pharma Group International operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AAPG.
Score Composition
Financial Data
More Stock Analysis
How is the AAPG UQS Score Calculated?
The UQS (Unified Quality Score) for Ascentage Pharma Group International is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Ascentage Pharma Group International's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Ascentage Pharma Group International is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.